EFTA02129741Set 10
2013-08-228p2,017w
Nobel Biocare Q2 revs slight ahead, EBIT below, EPS light, measured outlook (trading +10.5%)
• Raiffeisen O2 interest income better, fee & comm ahead, impairment losses in line (trading +2.5%)
• Phoenix Group
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02129741.pdf